PriceTargets.com logo

Lipella Pharmaceuticals - LIPO Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $2.00
  • Forecasted Upside: 181.29%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.71 As of 04/26/2024 01:00 AM ET
+0 (0.00%)

This chart shows the closing price for LIPO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Lipella Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for LIPO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for LIPO

Analyst Price Target is $2.00
▲ +181.29% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Lipella Pharmaceuticals in the last 3 months. The average price target is $2.00, with a high forecast of $2.00 and a low forecast of $2.00. The average price target represents a 181.29% upside from the last price of $0.71.

This chart shows the closing price for LIPO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 polled investment analysts is to buy stock in Lipella Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/4/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/2/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/3/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/1/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/30/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/28/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/28/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/27/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/9/2024Maxim GroupInitiated CoverageBuy$2.00Low
(Data available from 4/27/2019 forward)

News Sentiment Rating

0.06 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/30/2023
  • 3 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/30/2023
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/29/2023
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/29/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/28/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/27/2024
  • 2 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
3/28/2024
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/27/2024

Current Sentiment

  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Lipella Pharmaceuticals logo
Lipella Pharmaceuticals Inc., a biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. The company develops LP-10, a formulation of tacrolimus that has completed Phase 2a clinical trial for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; and LP-410, an oral liposomal formulation of tacrolimus for the treatment of oral graft-versus-host disease (GVHD). Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania.
Read More

Today's Range

Now: $0.71
Low: $0.71
High: $0.74

50 Day Range

MA: $0.79
Low: $0.67
High: $1.04

52 Week Range

Now: $0.71
Low: $0.64
High: $2.71

Volume

4,341 shs

Average Volume

29,390 shs

Market Capitalization

$4.44 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.33

Frequently Asked Questions

What sell-side analysts currently cover shares of Lipella Pharmaceuticals?

The following sell-side analysts have issued stock ratings on Lipella Pharmaceuticals in the last twelve months: Maxim Group.
View the latest analyst ratings for LIPO.

What is the current price target for Lipella Pharmaceuticals?

1 Wall Street analysts have set twelve-month price targets for Lipella Pharmaceuticals in the last year. Their average twelve-month price target is $2.00, suggesting a possible upside of 181.3%. Maxim Group has the highest price target set, predicting LIPO will reach $2.00 in the next twelve months. Maxim Group has the lowest price target set, forecasting a price of $2.00 for Lipella Pharmaceuticals in the next year.
View the latest price targets for LIPO.

What is the current consensus analyst rating for Lipella Pharmaceuticals?

Lipella Pharmaceuticals currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe LIPO will outperform the market and that investors should add to their positions of Lipella Pharmaceuticals.
View the latest ratings for LIPO.

What other companies compete with Lipella Pharmaceuticals?

Other companies that are similar to Lipella Pharmaceuticals include Cingulate, Genprex, Tharimmune, ZyVersa Therapeutics and Seelos Therapeutics. Learn More about companies similar to Lipella Pharmaceuticals.

How do I contact Lipella Pharmaceuticals' investor relations team?

Lipella Pharmaceuticals' physical mailing address is 7800 SUSQUEHANNA ST. SUITE 505, PITTSBURGH PA, 15208. The company's listed phone number is 412-901-0315 and its investor relations email address is [email protected]. The official website for Lipella Pharmaceuticals is lipella.com. Learn More about contacing Lipella Pharmaceuticals investor relations.